JNJ-7925476

JNJ-7925476 is a pharmaceutical drug developed by Johnson & Johnson, a multinational corporation that produces medical devices, pharmaceuticals, and consumer packaged goods. JNJ-7925476 is a dopamine agonist, a type of drug that activates dopamine receptors in the absence of that receptor's physiological ligand, the neurotransmitter dopamine.

History

JNJ-7925476 was developed as part of Johnson & Johnson's ongoing research into treatments for neurological disorders. The drug was designed to target dopamine receptors, which play a crucial role in the functioning of the central nervous system. Dopamine agonists like JNJ-7925476 are often used in the treatment of conditions such as Parkinson's disease and restless legs syndrome.

Mechanism of Action

As a dopamine agonist, JNJ-7925476 works by mimicking the action of dopamine, a type of neurotransmitter. Neurotransmitters are chemicals that transmit signals from a neuron to a target cell across a synapse. Dopamine is involved in several important pathways in the brain, including those that regulate mood, reward, addiction, and motor control.

JNJ-7925476 binds to dopamine receptors, particularly the D2 subtype, and activates them, thereby increasing the effect of dopamine in the brain. This can help to alleviate symptoms in conditions where dopamine function is impaired, such as Parkinson's disease.

Clinical Trials

JNJ-7925476 has undergone several rounds of clinical trials to assess its safety and efficacy. These trials are a crucial part of the drug development process, and involve testing the drug on a small number of healthy volunteers before moving on to larger trials involving patients with the condition the drug is intended to treat.

Side Effects

Like all drugs, JNJ-7925476 has the potential to cause side effects. These can vary widely in severity and frequency, depending on a range of factors including the dosage used, the individual patient's physiology, and the condition being treated.

Common side effects of dopamine agonists like JNJ-7925476 can include nausea, dizziness, and sleepiness. In some cases, these drugs can also cause more serious side effects, such as hallucinations, compulsive behaviors, and sudden sleep onset.

See Also

• Dopamine agonist
• Clinical trial
• Parkinson's disease
• Restless legs syndrome

This article is a stub related to pharmacology. You can help WikiMD by expanding it!

JNJ-7925476

• Maryanoff's antidepressant number 12B (1987) with tube model
  Maryanoff's antidepressant number 12B (1987) with tube model
• Pyrroloisoquinoline
  Pyrroloisoquinoline
• JNJ-7925476 according to AK Dutta
  JNJ-7925476 according to AK Dutta
• Pyrroloisoquinoline Synthesis
  Pyrroloisoquinoline Synthesis